Metachronous bladder recurrences after UTUC surgery may require more aggressive or different management than primary NMIBC. Bacillus Calmette Guérin (BCG) may be less effective in patients who develop ...
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) ...
Outcomes over 36 months support nogapendekin alfa inbakicept plus BCG in papillary-only BCG unresponsive NMIBC with a high cystectomy-free rate. Combination treatment including the interleukin-15 ...
Hosted on MSN
Bladder cancer treatment reprograms bone marrow to boost immune system's cancer-fighting ability
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...
Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results